Data layers Raw facts Calculated Model prediction AI interpretation

Company Overview

Stock NameBroncus-B
Stock Code02216
Company Full NameTo be extracted
IndustryHealthcare
Principal Activities專注於介入呼吸病學產品開發的醫療器械公司,利用專有全肺抵達導航技術,開發包括導航、診療的綜合介入呼吸病學平台,提供創新型肺部疾病解決方案,核心產品包括InterVapor熱蒸汽能量消融系統及RF-II射頻消融系統。
Listing Date2021-09-24
Listing Rules EraOld Rules
Listing Rules Chapter18A生物科技
Weighted Voting Rights (WVR)No
Registered Address (Mainland China)杭州市濱江區西興街道江陵路88號8幢8層801室
Business Address (Hong Kong)香港灣仔皇后大道東248號大新金融中心40樓
Place of IncorporationTo be extracted
Listing MethodTo be extracted
Listing BoardMain Board
Websitewww.broncus.com
Share Registrar香港中央證券登記有限公司 (Computershare Hong Kong Investor Services Limited)
Registrar Contact(852)2862 8628
A-Share/US Dual ListingNo

Offering Information

Offering Mechanism 18A生物科技
Offer PriceHK$ 18.70 / shares
Offer Price RangeFinal offer price only, no range
Lot Size500 shares
Entry ThresholdHK$ 9,350
Par ValueTo be extracted
Offer Period2021-09-13 to 2021-09-16
Global Offering Shares89,355,000 shares
HK Public Offer Shares (Initial)8,935,500 shares (10.0%)
Public Offer Lots (Initial)17,871lots (Pool A8,935lots,Pool B8,936lots)
International Placing Shares (Initial)80,419,500 shares (90.0%)
Offer Ratio~10.0%
Total Shares Post-IPO525,616,784 shares
Greenshoe (Over-allotment Option)Yes
Stabilizing Manager (Greenshoe)To be extracted
Cornerstone Share42.4%
Clawback TiersTo be extracted
Reallocation OptionNo
Total Global Offering SizeHK$ 1,670,938,500

Subscription Tiers

Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.

Pool A
Lots SubscribedShares SubscribedSubscription Amount (HKD)
1 lots 500 HK$ 9,350
2 lots 1,000 HK$ 18,700
3 lots 1,500 HK$ 28,050
4 lots 2,000 HK$ 37,400
5 lots 2,500 HK$ 46,750
6 lots 3,000 HK$ 56,100
7 lots 3,500 HK$ 65,450
8 lots 4,000 HK$ 74,800
9 lots 4,500 HK$ 84,150
10 lots 5,000 HK$ 93,500
12 lots 6,000 HK$ 112,200
14 lots 7,000 HK$ 130,900
16 lots 8,000 HK$ 149,600
18 lots 9,000 HK$ 168,300
20 lots 10,000 HK$ 187,000
30 lots 15,000 HK$ 280,500
40 lots 20,000 HK$ 374,000
50 lots 25,000 HK$ 467,500
60 lots 30,000 HK$ 561,000
70 lots 35,000 HK$ 654,500
80 lots 40,000 HK$ 748,000
90 lots 45,000 HK$ 841,500
100 lots 50,000 HK$ 935,000
120 lots 60,000 HK$ 1,122,000
140 lots 70,000 HK$ 1,309,000
160 lots 80,000 HK$ 1,496,000
180 lots 90,000 HK$ 1,683,000
200 lots 100,000 HK$ 1,870,000
400 lots 200,000 HK$ 3,740,000
Pool B
Lots SubscribedShares SubscribedSubscription Amount (HKD)
600 lots 300,000 HK$ 5,610,000
800 lots 400,000 HK$ 7,480,000
1,000 lots 500,000 HK$ 9,350,000
1,200 lots 600,000 HK$ 11,220,000
1,600 lots 800,000 HK$ 14,960,000
2,000 lots 1,000,000 HK$ 18,700,000
3,000 lots 1,500,000 HK$ 28,050,000
4,000 lots 2,000,000 HK$ 37,400,000
8,935 lots 4,467,500 HK$ 83,542,250

Stock Connect Inclusion Analysis

26Q4 Regular Review
Inclusion Pathway Regular Path
Avg Daily HK Mkt Cap HK$ 519.1M
Est. Threshold HK$ 9.69B
Analysis Result HK market cap below threshold, need +1767%

Valuation & Financials

Market Cap (at Offer Price)HK$ 9,829,033,860
Pre-IPO Valuation (Last Round)Not disclosed
P/E Ratio不適用(公司處於虧損狀態)
Profit/Loss Status虧損48.8百萬美元
Period-End Cash BalanceTo be extracted
Listing ExpensesTo be extracted
Listing Expenses / Funds RaisedTo be extracted
Total Pre-IPO InvestmentTo be extracted

Financial Data

Unit: '000 USD
Income Statement
Item 20192020
Revenue 8,0723,260
Cost of sales -2,094-754
Gross profit 5,9802,506
Other income and gains, net 3051,074
Selling and distribution expenses -8,609-6,352
Administrative expenses -8,855-7,742
Net finance costs -518-648
Profit before tax -32,450-48,484
Income tax expense -2-2
Profit for the year -32,351-48,386
Profit attributable to owners -31,939-48,237
Balance Sheet
Item 201920202021-04
Cash and cash equivalents 3,08518,768
Trade and bills receivables 3,1892,936
Inventories 1,8283,031
Total current assets 9,05626,702
Total assets 22,00339,887
Total current liabilities 14,14414,247
Total liabilities 95,882163,338
Total equity -73,878-124,451
Equity attributable to owners -72,364-121,523
Interest-bearing borrowings 5,7724,188799
Cash Flow Statement
Item 201920202021-04
Net cash from operating activities -15,800
Depreciation of PP&E 248287216
Depreciation of right-of-use assets 576658212
Amortisation of intangible assets 1,2491,247417
Purchase of PP&E -361-1,101-1,187
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
First Day CloseHK$ 15.0
First Day OpenHK$ 18.0
First Day Change-19.79%
First Day Volume19821500.0
First Day Turnover318630000.0
Use of Proceeds
1、49.9%(或約774.8百萬港元)分配予我們的核心產品; 2、18.5%(或約287.4百萬港元)分配予我們的其他產品及候選產品; 3、9.2%(或約143.0百萬港元)將用于為繼續擴大我們生產廠房的生產線提供資金; 4、13.2%(或約204.3百萬港元)將用于為通過潛在收購持續擴大產品組合提供資金; 5、9.2%(或約143.0百萬港元)將用于營運資金及其他一般公司用途。

Underwriting Syndicate

Joint Sponsors (2)
GOLDMAN SACHS (ASIA) L.L.C. CE ACC536 海通国际资本有限公司 CE ADQ859
Overall Coordinators (3)
GOLDMAN SACHS (ASIA) L.L.C. CE ACC536 海通国际证券有限公司 CE AAF806 Credit Suisse (Hong Kong) Limited CE AAO017
Joint Bookrunners (7)
GOLDMAN SACHS (ASIA) L.L.C. CE ACC536 海通国际证券有限公司 CE AAF806 Credit Suisse (Hong Kong) Limited CE AAO017 招银国际融资有限公司 CE AVM940 HUATAI FINANCIAL HOLDINGS (HONG KONG) LIMITED CE AOK809 CHINA INDUSTRIAL SECURITIES INTERNATIONAL CAPITAL LIMITED CE BAK956 CNCB (Hong Kong) Capital Limited CE AEQ982
Joint Lead Managers (7)
GOLDMAN SACHS (ASIA) L.L.C. CE ACC536 海通国际证券有限公司 CE AAF806 Credit Suisse (Hong Kong) Limited CE AAO017 招银国际融资有限公司 CE AVM940 HUATAI FINANCIAL HOLDINGS (HONG KONG) LIMITED CE AOK809 CHINA INDUSTRIAL SECURITIES INTERNATIONAL CAPITAL LIMITED CE BAK956 CNCB (Hong Kong) Capital Limited CE AEQ982

Cornerstone Investors

#Investor NameInvestment AmountShares Subscribed% of Offer Shares% of Total SharesLock-up PeriodEst. Unlock Date
1 Artisan China Post-Venture Master Fund LP 38,858,600 HKD — 2.30% — 6 months 2022-03-24
2 Cephei 77,717,200 HKD — 4.70% — 6 months 2022-03-24
3 Emerging Markets Healthcare Partners LLC 15,539,700 HKD — 0.90% — 6 months 2022-03-24
4 Lake Bleu Prime Healthcare Master Fund Limited 155,434,400 HKD — 9.30% — 6 months 2022-03-24
5 Snow Lake China Master Fund, Ltd. 77,717,200 HKD — 4.70% — 6 months 2022-03-24
6 Springhill Master Fund Limited 38,858,600 HKD — 2.30% — 6 months 2022-03-24
7 Summer Healthcare Fund, L.P. 77,717,200 HKD — 4.70% — 6 months 2022-03-24
8 The Valliance Fund 23,309,550 HKD — 1.40% — 6 months 2022-03-24
9 UBS Asset Management (Singapore) Ltd. 194,293,000 HKD — 11.60% — 6 months 2022-03-24
10 Worldwide Healthcare Partners LLC 7,769,850 HKD — 0.50% — 6 months 2022-03-24

Directors & Management

PositionChinese nameEnglish Name
Chairman趙亦偉—
Company Secretary王文豪、劉准羽—
No director data available.

Major Shareholders

Major Shareholders & Holdings控股股東QM12及BBL一致行動,連同訾先生及其他股東合共持有上市前50.41%權益,緊隨全球發售完成後約38.06%。其中訾先生持有29.89%(上市前)及22.57%(上市後),QM12持有20.52%及15.49%,BBL持有11.03%及8.32%。
About this page

This page shows Broncus-B (02216) prospectus details: offer price range, fundraise size, cornerstone investors, greenshoe, Pool A/B allocation and syndicate. For eligible IPOs it also provides a Stock Connect inclusion analysis, indicating the pathway and estimated timing for Southbound Connect admission; for A-share / US secondary listings, it additionally compares the other market's price, exchange rate and the H-share premium/discount. Data is parsed from the HKEX prospectus and related announcements. New to IPO subscription? See Hong Kong IPO Subscription 101.

Cibo — HK IPO Allotment Forecasts, Allottee Profiling & Stock Connect